Fetal Blood Sampling

Fetal blood sampling (FBS) is a prenatal procedure that can provide both diagnosis and therapy for genetic disorders in the fetus. It involves obtaining fetal blood through a needle inserted into the umbilical cord or a fetal vessel under ultrasound guidance. FBS was first performed in 1963 and has since been used for various indications, such as fetal anemia, thrombocytopenia, infection, metabolic disorders, and chromosomal or genetic disorders. FBS has the advantages of direct access to fetal circulation, early and rapid results, and the possibility of delivering therapeutic agents to the fetus. However, FBS also has some limitations and risks, such as technical difficulty, fetal loss, maternal sensitization, infection, bleeding, or preterm labor. Therefore, FBS should be performed only when indicated and with informed consent. The main objectives of this review are to provide an overview of the techniques and applications of FBS for genetic analysis of the fetus, to summarize the types and prevalence of genetic disorders that can be diagnosed by FBS, to highlight the clinical features, etiology, diagnosis, and treatment of each disorder, and to introduce the concept and principles of gene therapy and its potential for treating genetic disorders using FBS.

Fetal Blood Sampling for Genetic Analysis

FBS can be used to perform various techniques for genetic analysis of the fetus, such as karyotyping, fluorescence in situ hybridization (FISH), polymerase chain reaction (PCR), microarray, and next-generation sequencing (NGS). These techniques can detect different types and levels of genetic variations, such as chromosomal abnormalities, single-gene mutations, copy number variations, and epigenetic modifications. The choice of technique depends on the clinical indication, the availability of resources, and the type of genetic variation. Each technique has its own advantages and disadvantages in terms of accuracy, sensitivity, specificity, and turnaround time. FBS for genetic analysis can provide valuable information for prenatal diagnosis, prognosis, management, and counseling of genetic disorders. However, FBS for genetic analysis also raises ethical, legal, and social issues, such as informed consent, confidentiality, disclosure, termination, and discrimination.

Fetal Blood Sampling for Diagnosis of Genetic Disorders

FBS can be used to diagnose various types of genetic disorders that affect the fetus, such as chromosomal abnormalities, single-gene disorders, multifactorial disorders, and mitochondrial disorders. These disorders have different modes of inheritance, prevalence, and phenotypic expression. Some of the common genetic disorders that can be diagnosed by FBS are Down syndrome, cystic fibrosis, thalassemia, hemophilia, and Duchenne muscular dystrophy. For each disorder, FBS can provide information on the clinical features, etiology, diagnosis, and treatment. FBS can also help to determine the fetal genotype, phenotype, and risk of recurrence. Prenatal diagnosis by FBS can offer benefits such as early detection, timely intervention, informed decision-making, and psychological preparation. However, prenatal diagnosis by FBS can also pose risks such as fetal loss, maternal complications, false-positive or false-negative results, and ethical dilemmas.

Fetal Blood Sampling for Gene Therapy of Genetic Disorders

FBS can be used to deliver gene therapy to the fetus for treating genetic disorders. Gene therapy is a novel and promising approach that aims to correct or replace the defective gene or its product in the target cells. Gene therapy can be performed by using viral or non-viral vectors to transfer the therapeutic gene into the fetal blood cells ex vivo or in vivo. FBS can provide access to the fetal circulation and allow for the delivery of gene therapy to the fetus. FBS can also be used to monitor the efficacy and safety of gene therapy by measuring the expression and integration of the therapeutic gene. Some of the genetic disorders that can be treated by gene therapy using FBS are severe combined immunodeficiency (SCID), beta-thalassemia, sickle cell anemia, and hemophilia. Gene therapy by FBS can offer advantages such as early intervention, prevention of irreversible damage, and long-term correction. However, gene therapy by FBS can also face challenges such as technical difficulty, immune response, vector toxicity, insertional mutagenesis, and ethical concerns.

Conclusion

FBS is a prenatal procedure that can provide both diagnosis and therapy for genetic disorders in the fetus. FBS can be used to perform various techniques for genetic analysis, such as karyotyping, FISH, PCR, microarray, and NGS. FBS can also be used to diagnose various types of genetic disorders, such as chromosomal abnormalities, single-gene disorders, multifactorial disorders, and mitochondrial disorders. FBS can also be used to deliver gene therapy to the fetus for treating genetic disorders, such as SCID, beta-thalassemia, sickle cell anemia, and hemophilia. FBS can provide valuable information and intervention for prenatal management and counseling of genetic disorders. However, FBS also has some limitations and risks that need to be considered and minimized. FBS should be performed only when indicated and with informed consent. There are still gaps and challenges in the current knowledge and practice of FBS for genetic disorders. Future research and clinical trials are needed to improve the techniques, applications, and outcomes of FBS for genetic disorders.

References

  1. Al-Kouatly HB, et al. Fetal blood sampling: a review of indications, technique, and complications. J Matern Fetal Neonatal Med. 2019 Nov;32(22):3777-3784.
  2. Karnpean R. Fetal blood sampling in prenatal diagnosis of thalassemia at late pregnancy. J Med Assoc Thai. 2014 Apr;97 Suppl 4:S49-55.
  3. Chaitanya KV. Diagnostics and Gene Therapy for Human Genetic Disorders. CRC Press; 2022.
  4. David AL, et al. Fetal gene therapy: potential and limitations. Arch Dis Child Fetal Neonatal Ed. 2011 May;96(3):F227-31.
  5. De Coppi P, et al. In utero stem cell transplantation and gene therapy: rationale, history, and recent advances toward clinical application. Mol Ther Methods Clin Dev. 2016 Aug 17;3:16069.
  6. DeWeerdt S. Prenatal gene therapy offers the earliest possible cure. Nature. 2018 Dec 12;564(7734):S10-S11.
  7. Giannakopoulou E, et al. Prenatal diagnosis of inherited disorders: an update on molecular techniques and their application in clinical practice. Expert Rev Mol Diagn. 2019 Oct;19(10):865-877.
  8. Ginn SL, et al. Gene therapy clinical trials worldwide to 2017: An update. J Gene Med. 2018 Mar;20(5):e3015.
  9. Hui L, et al. Prenatal diagnosis of fetal genetic disorders: a population-based evaluation of the impact of non-invasive prenatal testing in high-risk women in Victoria, Australia. Prenat Diagn. 2020 Jan;40(1):36-44.
  10. Kaur S, et al. Gene therapy for inherited disorders: an update for pediatricians and pediatric researchers. Pediatr Res. 2020 Jan;87(2):205-212.
  11. Lee CQ, et al. In utero gene editing for monogenic lung disease. Sci Transl Med. 2019 Apr 17;11(488):eaav8375.
  12. Mattar CNZ, et al. Systemic Delivery of scAAV9 in Fetal Macaques to Target Neuromuscular Tissues. Mol Ther Methods Clin Dev. 2018 Sep 21;10:191-200.
  13. Peranteau WH, et al. In utero gene therapy rescues microcephaly caused by Pqbp1-hypofunction in neural stem progenitor cells. Mol Ther Methods Clin Dev. 2019 Feb 22;13:334-342.
  14. Ranzinger J, et al. CRISPR/Cas9-mediated genome engineering: an adeno-associated viral (AAV) vector toolbox. Biotechnol J. 2015 Nov;10(11):1564-71.
For research use only. Not intended for any clinical use.